Angiosarcoma Treatment Market - Top Companies and Manufacturers

In the News

• Novartis announced that the U.S. Food and Drug Administration (FDA) had granted commercial authorization for a multi-product gene therapy manufacturing facility in Durham, North Carolina. This approval allows the 170,000 square foot state-of-the-art facility to manufacture, test and commercialize Zolgensma, as well as produce gene therapy products for current and future clinical trials.
• Amgen announced the completion of its acquisition of Teneobio, Inc. was previously announced with a cash payment of $900 million. The acquisition includes Teneobio's proprietary specific and multispecific antibody technologies, which complement Amgen's existing antibody capabilities and the BiTE platform, and will enable significant acceleration and efficiency in the discovery and development of new molecules.